PMID- 27535294
OWN - NLM
STAT- MEDLINE
DCOM- 20170308
LR  - 20181202
IS  - 1973-9478 (Electronic)
IS  - 1120-009X (Linking)
VI  - 28
IP  - 6
DP  - 2016 Dec
TI  - Trabectedin for sarcomas in daily clinical practice: analysis of 45 patients 
      treated in a French institution.
PG  - 494-499
AB  - INTRODUCTION: The active clinical research programme of trabectedin continues to 
      improve knowledge on the therapeutic activity and toxicity of the drug in the 
      treatment of soft tissue sarcomas (STS). In contrast, limited number of data is 
      available on its use outside of clinical trials. PATIENTS AND METHODS: We 
      retrospectively analysed efficacy and safety of trabectedin when given in daily 
      practice to patients with advanced/recurrent STS. Outcomes were compared with 
      previously published works including clinical and retrospective studies. RESULTS: 
      Forty-five patients received trabectedin between January 2005 and May 2014. 
      Sarcomas were histologically heterogeneous in our cohort (37.9% of other types of 
      sarcomas than L-sarcomas). Our patients had poor baseline health status (ECOG >/= 2 
      [17.8%]) and had received multiple previous lines of chemotherapy. Patients 
      received a median of five cycles of treatment (1-22). The objective response rate 
      was statistically superior in our study (37.8%) compared to the other works. 
      However, median PFS was similar. Trabectedin-related serious adverse events (AEs) 
      induced hospitalizations and treatment discontinuation in 22 and 15% of patients. 
      CONCLUSION: This analysis confirms the efficacy of trabectedin in clinical 
      practice (with a third of patients experiencing prolonged disease control) and 
      highlighted the importance of its administration as early line therapy to allow 
      the best management of serious AEs.
FAU - Daupin, Johanne
AU  - Daupin J
AD  - a Department of Pharmacy , Hopital Tenon (Hopitaux Universitaires de 
      l'Est-Parisien, AP-HP) , Paris , France.
AD  - b Faculty of Pharmacy , Universite Paris Descartes (Paris 5) , Paris , France.
FAU - Paubel, Pascal
AU  - Paubel P
AD  - b Faculty of Pharmacy , Universite Paris Descartes (Paris 5) , Paris , France.
FAU - Fillon, Julie
AU  - Fillon J
AD  - a Department of Pharmacy , Hopital Tenon (Hopitaux Universitaires de 
      l'Est-Parisien, AP-HP) , Paris , France.
FAU - Debrix, Isabelle
AU  - Debrix I
AD  - a Department of Pharmacy , Hopital Tenon (Hopitaux Universitaires de 
      l'Est-Parisien, AP-HP) , Paris , France.
FAU - Soares, Daniele G
AU  - Soares DG
AD  - c Department of Medical Oncology and Cellular Therapy , APREC (Alliance Pour la 
      Recherche En Cancerologie), Hopital Tenon (Hopitaux Universitaires de 
      l'Est-Parisien, AP-HP) , Paris , France.
FAU - Lotz, Jean-Pierre
AU  - Lotz JP
AD  - c Department of Medical Oncology and Cellular Therapy , APREC (Alliance Pour la 
      Recherche En Cancerologie), Hopital Tenon (Hopitaux Universitaires de 
      l'Est-Parisien, AP-HP) , Paris , France.
AD  - d Institut Universitaire de Cancerologie (IUC) , Sorbonne Universites, Universite 
      Pierre et Marie Curie (UPMC Univ Paris 06) , Paris , France.
LA  - eng
PT  - Journal Article
DEP - 20160818
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Dioxoles)
RN  - 0 (Tetrahydroisoquinolines)
RN  - ID0YZQ2TCP (Trabectedin)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/*therapeutic use
MH  - Dioxoles/administration & dosage/adverse effects/*therapeutic use
MH  - Disease-Free Survival
MH  - France
MH  - Humans
MH  - Retrospective Studies
MH  - Sarcoma/diagnosis/*drug therapy
MH  - Tetrahydroisoquinolines/administration & dosage/adverse effects/*therapeutic use
MH  - Trabectedin
OTO - NOTNLM
OT  - Clinical practice
OT  - Efficacy
OT  - Safety
OT  - Soft tissue sarcomas
OT  - Trabectedin
EDAT- 2016/08/19 06:00
MHDA- 2017/03/09 06:00
CRDT- 2016/08/19 06:00
PHST- 2016/08/19 06:00 [pubmed]
PHST- 2017/03/09 06:00 [medline]
PHST- 2016/08/19 06:00 [entrez]
AID - 10.1080/1120009X.2016.1218179 [doi]
PST - ppublish
SO  - J Chemother. 2016 Dec;28(6):494-499. doi: 10.1080/1120009X.2016.1218179. Epub 
      2016 Aug 18.